+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Upadacitinib Market by Form (Solution, Tablet), Therapeutic Area (Ankylosing Spondylitis, Atopic Dermatitis, Crohn's Disease), End-Users, Distribution Channel - Global Forecast 2025-2030- Product Image
Upadacitinib Market by Form (Solution, Tablet), Therapeutic Area (Ankylosing Spondylitis, Atopic Dermatitis, Crohn's Disease), End-Users, Distribution Channel - Global Forecast 2025-2030- Product Image
Sale

Upadacitinib Market by Form (Solution, Tablet), Therapeutic Area (Ankylosing Spondylitis, Atopic Dermatitis, Crohn's Disease), End-Users, Distribution Channel - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 183 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 6090163
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Senior decision-makers seeking insights into targeted immunomodulation therapies will find the Upadacitinib Market analysis essential for understanding current trends, emerging clinical strategies, and competitive positioning in chronic inflammatory disease management. This executive summary distills actionable intelligence to drive strategy across R&D, commercialization, and access optimization.

Market Snapshot: Upadacitinib Market Size and Growth Outlook

The Upadacitinib Market grew from USD 303.47 million in 2024 to USD 325.20 million in 2025. It is projected to sustain robust expansion, advancing at a CAGR of 7.41% to reach USD 466.22 million by 2030. Rising prevalence of autoimmune conditions, coupled with the demand for more convenient, orally administered options, is reshaping market adoption models. Stakeholder attention centers on clinical versatility, enhanced patient adherence, and evolving payer frameworks driving sector momentum.

Scope & Segmentation

The report conducts a comprehensive assessment of the upadacitinib landscape by analyzing critical market segments, care settings, and regional opportunities:

  • Form: Solution, Tablet
  • Therapeutic Area: Ankylosing spondylitis, Atopic dermatitis, Crohn’s disease, Psoriatic arthritis, Rheumatoid arthritis, Ulcerative colitis
  • End-Users: Hospitals and clinics, Outpatient care, Specialty clinics
  • Distribution Channel: Offline, Online
  • Regions: Americas (United States, Canada, Mexico, Brazil, Argentina), Europe, Middle East & Africa (United Kingdom, Germany, France, Russia, Italy, Spain, United Arab Emirates, Saudi Arabia, South Africa, Denmark, Netherlands, Qatar, Finland, Sweden, Nigeria, Egypt, Turkey, Israel, Norway, Poland, Switzerland), Asia-Pacific (China, India, Japan, Australia, South Korea, Indonesia, Thailand, Philippines, Malaysia, Singapore, Vietnam, Taiwan)
  • Key Industry Players: AbbVie Inc., Cayman Chemical Company, Bayer AG, Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Cipla Limited, Daiichi Sankyo Company, Limited, GlaxoSmithKline plc, Incyte Corporation, Merck & Co., Inc., Pfizer Inc, Regeneron Pharmaceuticals, Inc., Sun Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Limited, Aarti Pharmalabs Limited, Anant Pharmaceuticals Pvt. Ltd., BOCSCI Inc.

Key Takeaways

  • Upadacitinib’s selective JAK inhibition allows it to intervene at the molecular level, redirecting immune activity for various chronic inflammatory and autoimmune indications where standard treatments have proven insufficient.
  • Evolving therapy models now prioritize precision intervention, supported by increasing adoption of molecular profiling and biomarker-driven patient selection—an approach that optimizes both clinical success and resource allocation.
  • Clinical workflows are benefiting from digital health integration, as telehealth, remote monitoring, and patient-reported outcome platforms strengthen real-time decision-making and collaborative disease management among providers.
  • Competitive strategies focus on lifecycle management, pipeline expansion, and strategic manufacturing alliances that reinforce supply reliability and differentiate service quality across care settings and geographies.
  • Education and multidisciplinary dialogue are being supported through investment in academic partnerships and professional training initiatives, ensuring that stakeholders are equipped to implement evolving treatment protocols effectively.

Tariff Impact and Supply Chain Implications

New tariff measures in the United States are influencing upadacitinib procurement and distribution strategies. Increased import duties affecting both raw materials and finished products are prompting manufacturers and distributors to reassess cost structures and rethink supply chain dependencies. Organizations are exploring domestic partnerships and local manufacturing to ensure resilience. Value-based pricing negotiations with payers and advocacy with regulatory bodies are emerging in response to shifting trade environments, guiding strategic procurement decisions and facilitating patient access.

Methodology & Data Sources

This report applies a hybrid methodology that integrates primary research—through interviews and surveys with clinical experts, key opinion leaders, and payers—and secondary analysis from regulatory documents, scientific literature, and public databases. Data triangulation and quality assurance protocols bolster analytical robustness and ensure that findings are both credible and actionable.

Why This Report Matters

  • Enables strategic planning by providing a detailed segmentation and competitive landscape for the upadacitinib market.
  • Empowers decision-makers with insight into regulatory, clinical, and procurement trends that influence therapy adoption and market entry.
  • Supports informed investments in innovation, market expansion, and patient engagement initiatives through actionable, evidence-based recommendations.

Conclusion

This report offers a concise, actionable analysis to help stakeholders optimize development, commercialization, and access strategies in the evolving upadacitinib market. Leverage these insights for sustained competitive advantage and improved patient outcomes in chronic inflammatory disease management.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Widening label approvals for upadacitinib drive expansion beyond rheumatoid arthritis into atopic dermatitis and ulcerative colitis
5.2. SELECT program outcomes fuel new market opportunities and competitive positioning for upadacitinib in psoriatic arthritis
5.3. Emerging market penetration limited by regulatory barriers and affordability issues for upadacitinib in Latin America and Asia
5.4. Early patient support programs and digital engagement platforms emerge as critical factors in upadacitinib treatment uptake
5.5. Health technology assessments tighten reimbursement criteria for upadacitinib in Europe amid cost-effectiveness concerns
5.6. Escalating competition from JAK inhibitor biosimilars and next-generation molecules pressure upadacitinib pricing strategies
5.7. Mounting real-world safety data challenge upadacitinib risk profile after extended JAK inhibitor trials
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Upadacitinib Market, by Form
8.1. Introduction
8.2. Solution
8.3. Tablet
9. Upadacitinib Market, by Therapeutic Area
9.1. Introduction
9.2. Ankylosing Spondylitis
9.3. Atopic Dermatitis
9.4. Crohn's Disease
9.5. Psoriatic Arthritis
9.6. Rheumatoid Arthritis
9.7. Ulcerative Colitis
10. Upadacitinib Market, by End-Users
10.1. Introduction
10.2. Hospitals & Clinics
10.3. Outpatient Care
10.4. Speciality Clinics
11. Upadacitinib Market, by Distribution Channel
11.1. Introduction
11.2. Offline
11.3. Online
12. Americas Upadacitinib Market
12.1. Introduction
12.2. United States
12.3. Canada
12.4. Mexico
12.5. Brazil
12.6. Argentina
13. Europe, Middle East & Africa Upadacitinib Market
13.1. Introduction
13.2. United Kingdom
13.3. Germany
13.4. France
13.5. Russia
13.6. Italy
13.7. Spain
13.8. United Arab Emirates
13.9. Saudi Arabia
13.10. South Africa
13.11. Denmark
13.12. Netherlands
13.13. Qatar
13.14. Finland
13.15. Sweden
13.16. Nigeria
13.17. Egypt
13.18. Turkey
13.19. Israel
13.20. Norway
13.21. Poland
13.22. Switzerland
14. Asia-Pacific Upadacitinib Market
14.1. Introduction
14.2. China
14.3. India
14.4. Japan
14.5. Australia
14.6. South Korea
14.7. Indonesia
14.8. Thailand
14.9. Philippines
14.10. Malaysia
14.11. Singapore
14.12. Vietnam
14.13. Taiwan
15. Competitive Landscape
15.1. Market Share Analysis, 2024
15.2. FPNV Positioning Matrix, 2024
15.3. Competitive Analysis
15.3.1. AbbVie Inc.
15.3.2. Cayman Chemical Company
15.3.3. Bayer AG
15.3.4. Boehringer Ingelheim GmbH
15.3.5. Bristol-Myers Squibb Company
15.3.6. Cipla Limited
15.3.7. Daiichi Sankyo Company, Limited
15.3.8. GlaxoSmithKline plc
15.3.9. Incyte Corporation
15.3.10. Merck & Co., Inc.
15.3.11. Pfizer Inc
15.3.12. Regeneron Pharmaceuticals, Inc.
15.3.13. Sun Pharmaceutical Industries Ltd.
15.3.14. Takeda Pharmaceutical Company Limited
15.3.15. Aarti Pharmalabs Limited
15.3.16. Anant Pharmaceuticals Pvt. Ltd.
15.3.17. BOCSCI Inc.
16. Research AI17. Research Statistics18. Research Contacts19. Research Articles20. Appendix
List of Figures
FIGURE 1. UPADACITINIB MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL UPADACITINIB MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL UPADACITINIB MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL UPADACITINIB MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL UPADACITINIB MARKET SIZE, BY FORM, 2024 VS 2030 (%)
FIGURE 6. GLOBAL UPADACITINIB MARKET SIZE, BY FORM, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL UPADACITINIB MARKET SIZE, BY THERAPEUTIC AREA, 2024 VS 2030 (%)
FIGURE 8. GLOBAL UPADACITINIB MARKET SIZE, BY THERAPEUTIC AREA, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL UPADACITINIB MARKET SIZE, BY END-USERS, 2024 VS 2030 (%)
FIGURE 10. GLOBAL UPADACITINIB MARKET SIZE, BY END-USERS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL UPADACITINIB MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 12. GLOBAL UPADACITINIB MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. AMERICAS UPADACITINIB MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 14. AMERICAS UPADACITINIB MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. UNITED STATES UPADACITINIB MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 16. UNITED STATES UPADACITINIB MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. EUROPE, MIDDLE EAST & AFRICA UPADACITINIB MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. EUROPE, MIDDLE EAST & AFRICA UPADACITINIB MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. ASIA-PACIFIC UPADACITINIB MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. ASIA-PACIFIC UPADACITINIB MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. UPADACITINIB MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 22. UPADACITINIB MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 23. UPADACITINIB MARKET: RESEARCHAI
FIGURE 24. UPADACITINIB MARKET: RESEARCHSTATISTICS
FIGURE 25. UPADACITINIB MARKET: RESEARCHCONTACTS
FIGURE 26. UPADACITINIB MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. UPADACITINIB MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL UPADACITINIB MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL UPADACITINIB MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL UPADACITINIB MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL UPADACITINIB MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL UPADACITINIB MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL UPADACITINIB MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL UPADACITINIB MARKET SIZE, BY FORM, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL UPADACITINIB MARKET SIZE, BY FORM, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL UPADACITINIB MARKET SIZE, BY SOLUTION, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL UPADACITINIB MARKET SIZE, BY SOLUTION, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL UPADACITINIB MARKET SIZE, BY TABLET, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL UPADACITINIB MARKET SIZE, BY TABLET, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL UPADACITINIB MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL UPADACITINIB MARKET SIZE, BY THERAPEUTIC AREA, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL UPADACITINIB MARKET SIZE, BY ANKYLOSING SPONDYLITIS, BY REGION, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL UPADACITINIB MARKET SIZE, BY ANKYLOSING SPONDYLITIS, BY REGION, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL UPADACITINIB MARKET SIZE, BY ATOPIC DERMATITIS, BY REGION, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL UPADACITINIB MARKET SIZE, BY ATOPIC DERMATITIS, BY REGION, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL UPADACITINIB MARKET SIZE, BY CROHN'S DISEASE, BY REGION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL UPADACITINIB MARKET SIZE, BY CROHN'S DISEASE, BY REGION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL UPADACITINIB MARKET SIZE, BY PSORIATIC ARTHRITIS, BY REGION, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL UPADACITINIB MARKET SIZE, BY PSORIATIC ARTHRITIS, BY REGION, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL UPADACITINIB MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY REGION, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL UPADACITINIB MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY REGION, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL UPADACITINIB MARKET SIZE, BY ULCERATIVE COLITIS, BY REGION, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL UPADACITINIB MARKET SIZE, BY ULCERATIVE COLITIS, BY REGION, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL UPADACITINIB MARKET SIZE, BY END-USERS, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL UPADACITINIB MARKET SIZE, BY END-USERS, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL UPADACITINIB MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL UPADACITINIB MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL UPADACITINIB MARKET SIZE, BY OUTPATIENT CARE, BY REGION, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL UPADACITINIB MARKET SIZE, BY OUTPATIENT CARE, BY REGION, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL UPADACITINIB MARKET SIZE, BY SPECIALITY CLINICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL UPADACITINIB MARKET SIZE, BY SPECIALITY CLINICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL UPADACITINIB MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL UPADACITINIB MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL UPADACITINIB MARKET SIZE, BY OFFLINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL UPADACITINIB MARKET SIZE, BY OFFLINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL UPADACITINIB MARKET SIZE, BY ONLINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL UPADACITINIB MARKET SIZE, BY ONLINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 43. AMERICAS UPADACITINIB MARKET SIZE, BY FORM, 2018-2024 (USD MILLION)
TABLE 44. AMERICAS UPADACITINIB MARKET SIZE, BY FORM, 2025-2030 (USD MILLION)
TABLE 45. AMERICAS UPADACITINIB MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
TABLE 46. AMERICAS UPADACITINIB MARKET SIZE, BY THERAPEUTIC AREA, 2025-2030 (USD MILLION)
TABLE 47. AMERICAS UPADACITINIB MARKET SIZE, BY END-USERS, 2018-2024 (USD MILLION)
TABLE 48. AMERICAS UPADACITINIB MARKET SIZE, BY END-USERS, 2025-2030 (USD MILLION)
TABLE 49. AMERICAS UPADACITINIB MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 50. AMERICAS UPADACITINIB MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 51. AMERICAS UPADACITINIB MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 52. AMERICAS UPADACITINIB MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 53. UNITED STATES UPADACITINIB MARKET SIZE, BY FORM, 2018-2024 (USD MILLION)
TABLE 54. UNITED STATES UPADACITINIB MARKET SIZE, BY FORM, 2025-2030 (USD MILLION)
TABLE 55. UNITED STATES UPADACITINIB MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
TABLE 56. UNITED STATES UPADACITINIB MARKET SIZE, BY THERAPEUTIC AREA, 2025-2030 (USD MILLION)
TABLE 57. UNITED STATES UPADACITINIB MARKET SIZE, BY END-USERS, 2018-2024 (USD MILLION)
TABLE 58. UNITED STATES UPADACITINIB MARKET SIZE, BY END-USERS, 2025-2030 (USD MILLION)
TABLE 59. UNITED STATES UPADACITINIB MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 60. UNITED STATES UPADACITINIB MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 61. UNITED STATES UPADACITINIB MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 62. UNITED STATES UPADACITINIB MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 63. CANADA UPADACITINIB MARKET SIZE, BY FORM, 2018-2024 (USD MILLION)
TABLE 64. CANADA UPADACITINIB MARKET SIZE, BY FORM, 2025-2030 (USD MILLION)
TABLE 65. CANADA UPADACITINIB MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
TABLE 66. CANADA UPADACITINIB MARKET SIZE, BY THERAPEUTIC AREA, 2025-2030 (USD MILLION)
TABLE 67. CANADA UPADACITINIB MARKET SIZE, BY END-USERS, 2018-2024 (USD MILLION)
TABLE 68. CANADA UPADACITINIB MARKET SIZE, BY END-USERS, 2025-2030 (USD MILLION)
TABLE 69. CANADA UPADACITINIB MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 70. CANADA UPADACITINIB MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 71. MEXICO UPADACITINIB MARKET SIZE, BY FORM, 2018-2024 (USD MILLION)
TABLE 72. MEXICO UPADACITINIB MARKET SIZE, BY FORM, 2025-2030 (USD MILLION)
TABLE 73. MEXICO UPADACITINIB MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
TABLE 74. MEXICO UPADACITINIB MARKET SIZE, BY THERAPEUTIC AREA, 2025-2030 (USD MILLION)
TABLE 75. MEXICO UPADACITINIB MARKET SIZE, BY END-USERS, 2018-2024 (USD MILLION)
TABLE 76. MEXICO UPADACITINIB MARKET SIZE, BY END-USERS, 2025-2030 (USD MILLION)
TABLE 77. MEXICO UPADACITINIB MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 78. MEXICO UPADACITINIB MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 79. BRAZIL UPADACITINIB MARKET SIZE, BY FORM, 2018-2024 (USD MILLION)
TABLE 80. BRAZIL UPADACITINIB MARKET SIZE, BY FORM, 2025-2030 (USD MILLION)
TABLE 81. BRAZIL UPADACITINIB MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
TABLE 82. BRAZIL UPADACITINIB MARKET SIZE, BY THERAPEUTIC AREA, 2025-2030 (USD MILLION)
TABLE 83. BRAZIL UPADACITINIB MARKET SIZE, BY END-USERS, 2018-2024 (USD MILLION)
TABLE 84. BRAZIL UPADACITINIB MARKET SIZE, BY END-USERS, 2025-2030 (USD MILLION)
TABLE 85. BRAZIL UPADACITINIB MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 86. BRAZIL UPADACITINIB MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 87. ARGENTINA UPADACITINIB MARKET SIZE, BY FORM, 2018-2024 (USD MILLION)
TABLE 88. ARGENTINA UPADACITINIB MARKET SIZE, BY FORM, 2025-2030 (USD MILLION)
TABLE 89. ARGENTINA UPADACITINIB MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
TABLE 90. ARGENTINA UPADACITINIB MARKET SIZE, BY THERAPEUTIC AREA, 2025-2030 (USD MILLION)
TABLE 91. ARGENTINA UPADACITINIB MARKET SIZE, BY END-USERS, 2018-2024 (USD MILLION)
TABLE 92. ARGENTINA UPADACITINIB MARKET SIZE, BY END-USERS, 2025-2030 (USD MILLION)
TABLE 93. ARGENTINA UPADACITINIB MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 94. ARGENTINA UPADACITINIB MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 95. EUROPE, MIDDLE EAST & AFRICA UPADACITINIB MARKET SIZE, BY FORM, 2018-2024 (USD MILLION)
TABLE 96. EUROPE, MIDDLE EAST & AFRICA UPADACITINIB MARKET SIZE, BY FORM, 2025-2030 (USD MILLION)
TABLE 97. EUROPE, MIDDLE EAST & AFRICA UPADACITINIB MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
TABLE 98. EUROPE, MIDDLE EAST & AFRICA UPADACITINIB MARKET SIZE, BY THERAPEUTIC AREA, 2025-2030 (USD MILLION)
TABLE 99. EUROPE, MIDDLE EAST & AFRICA UPADACITINIB MARKET SIZE, BY END-USERS, 2018-2024 (USD MILLION)
TABLE 100. EUROPE, MIDDLE EAST & AFRICA UPADACITINIB MARKET SIZE, BY END-USERS, 2025-2030 (USD MILLION)
TABLE 101. EUROPE, MIDDLE EAST & AFRICA UPADACITINIB MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 102. EUROPE, MIDDLE EAST & AFRICA UPADACITINIB MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 103. EUROPE, MIDDLE EAST & AFRICA UPADACITINIB MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 104. EUROPE, MIDDLE EAST & AFRICA UPADACITINIB MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 105. UNITED KINGDOM UPADACITINIB MARKET SIZE, BY FORM, 2018-2024 (USD MILLION)
TABLE 106. UNITED KINGDOM UPADACITINIB MARKET SIZE, BY FORM, 2025-2030 (USD MILLION)
TABLE 107. UNITED KINGDOM UPADACITINIB MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
TABLE 108. UNITED KINGDOM UPADACITINIB MARKET SIZE, BY THERAPEUTIC AREA, 2025-2030 (USD MILLION)
TABLE 109. UNITED KINGDOM UPADACITINIB MARKET SIZE, BY END-USERS, 2018-2024 (USD MILLION)
TABLE 110. UNITED KINGDOM UPADACITINIB MARKET SIZE, BY END-USERS, 2025-2030 (USD MILLION)
TABLE 111. UNITED KINGDOM UPADACITINIB MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 112. UNITED KINGDOM UPADACITINIB MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 113. GERMANY UPADACITINIB MARKET SIZE, BY FORM, 2018-2024 (USD MILLION)
TABLE 114. GERMANY UPADACITINIB MARKET SIZE, BY FORM, 2025-2030 (USD MILLION)
TABLE 115. GERMANY UPADACITINIB MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
TABLE 116. GERMANY UPADACITINIB MARKET SIZE, BY THERAPEUTIC AREA, 2025-2030 (USD MILLION)
TABLE 117. GERMANY UPADACITINIB MARKET SIZE, BY END-USERS, 2018-2024 (USD MILLION)
TABLE 118. GERMANY UPADACITINIB MARKET SIZE, BY END-USERS, 2025-2030 (USD MILLION)
TABLE 119. GERMANY UPADACITINIB MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 120. GERMANY UPADACITINIB MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 121. FRANCE UPADACITINIB MARKET SIZE, BY FORM, 2018-2024 (USD MILLION)
TABLE 122. FRANCE UPADACITINIB MARKET SIZE, BY FORM, 2025-2030 (USD MILLION)
TABLE 123. FRANCE UPADACITINIB MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
TABLE 124. FRANCE UPADACITINIB MARKET SIZE, BY THERAPEUTIC AREA, 2025-2030 (USD MILLION)
TABLE 125. FRANCE UPADACITINIB MARKET SIZE, BY END-USERS, 2018-2024 (USD MILLION)
TABLE 126. FRANCE UPADACITINIB MARKET SIZE, BY END-USERS, 2025-2030 (USD MILLION)
TABLE 127. FRANCE UPADACITINIB MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 128. FRANCE UPADACITINIB MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 129. RUSSIA UPADACITINIB MARKET SIZE, BY FORM, 2018-2024 (USD MILLION)
TABLE 130. RUSSIA UPADACITINIB MARKET SIZE, BY FORM, 2025-2030 (USD MILLION)
TABLE 131. RUSSIA UPADACITINIB MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
TABLE 132. RUSSIA UPADACITINIB MARKET SIZE, BY THERAPEUTIC AREA, 2025-2030 (USD MILLION)
TABLE 133. RUSSIA UPADACITINIB MARKET SIZE, BY END-USERS, 2018-2024 (USD MILLION)
TABLE 134. RUSSIA UPADACITINIB MARKET SIZE, BY END-USERS, 2025-2030 (USD MILLION)
TABLE 135. RUSSIA UPADACITINIB MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 136. RUSSIA UPADACITINIB MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 137. ITALY UPADACITINIB MARKET SIZE, BY FORM, 2018-2024 (USD MILLION)
TABLE 138. ITALY UPADACITINIB MARKET SIZE, BY FORM, 2025-2030 (USD MILLION)
TABLE 139. ITALY UPADACITINIB MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
TABLE 140. ITALY UPADACITINIB MARKET SIZE, BY THERAPEUTIC AREA, 2025-2030 (USD MILLION)
TABLE 141. ITALY UPADACITINIB MARKET SIZE, BY END-USERS, 2018-2024 (USD MILLION)
TABLE 142. ITALY UPADACITINIB MARKET SIZE, BY END-USERS, 2025-2030 (USD MILLION)
TABLE 143. ITALY UPADACITINIB MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 144. ITALY UPADACITINIB MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 145. SPAIN UPADACITINIB MARKET SIZE, BY FORM, 2018-2024 (USD MILLION)
TABLE 146. SPAIN UPADACITINIB MARKET SIZE, BY FORM, 2025-2030 (USD MILLION)
TABLE 147. SPAIN UPADACITINIB MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
TABLE 148. SPAIN UPADACITINIB MARKET SIZE, BY THERAPEUTIC AREA, 2025-2030 (USD MILLION)
TABLE 149. SPAIN UPADACITINIB MARKET SIZE, BY END-USERS, 2018-2024 (USD MILLION)
TABLE 150. SPAIN UPADACITINIB MARKET SIZE, BY END-USERS, 2025-2030 (USD MILLION)
TABLE 151. SPAIN UPADACITINIB MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 152. SPAIN UPADACITINIB MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 153. UNITED ARAB EMIRATES UPADACITINIB MARKET SIZE, BY FORM, 2018-2024 (USD MILLION)
TABLE 154. UNITED ARAB EMIRATES UPADACITINIB MARKET SIZE, BY FORM, 2025-2030 (USD MILLION)
TABLE 155. UNITED ARAB EMIRATES UPADACITINIB MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
TABLE 156. UNITED ARAB EMIRATES UPADACITINIB MARKET SIZE, BY THERAPEUTIC AREA, 2025-2030 (USD MILLION)
TABLE 157. UNITED ARAB EMIRATES UPADACITINIB MARKET SIZE, BY END-USERS, 2018-2024 (USD MILLION)
TABLE 158. UNITED ARAB EMIRATES UPADACITINIB MARKET SIZE, BY END-USERS, 2025-2030 (USD MILLION)
TABLE 159. UNITED ARAB EMIRATES UPADACITINIB MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 160. UNITED ARAB EMIRATES UPADACITINIB MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 161. SAUDI ARABIA UPADACITINIB MARKET SIZE, BY FORM, 2018-2024 (USD MILLION)
TABLE 162. SAUDI ARABIA UPADACITINIB MARKET SIZE, BY FORM, 2025-2030 (USD MILLION)
TABLE 163. SAUDI ARABIA UPADACITINIB MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
TABLE 164. SAUDI ARABIA UPADACITINIB MARKET SIZE, BY THERAPEUTIC AREA, 2025-2030 (USD MILLION)
TABLE 165. SAUDI ARABIA UPADACITINIB MARKET SIZE, BY END-USERS, 2018-2024 (USD MILLION)
TABLE 166. SAUDI ARABIA UPADACITINIB MARKET SIZE, BY END-USERS, 2025-2030 (USD MILLION)
TABLE 167. SAUDI ARABIA UPADACITINIB MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 168. SAUDI ARABIA UPADACITINIB MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 169. SOUTH AFRICA UPADACITINIB MARKET SIZE, BY FORM, 2018-2024 (USD MILLION)
TABLE 170. SOUTH AFRICA UPADACITINIB MARKET SIZE, BY FORM, 2025-2030 (USD MILLION)
TABLE 171. SOUTH AFRICA UPADACITINIB MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
TABLE 172. SOUTH AFRICA UPADACITINIB MARKET SIZE, BY THERAPEUTIC AREA, 2025-2030 (USD MILLION)
TABLE 173. SOUTH AFRICA UPADACITINIB MARKET SIZE, BY END-USERS, 2018-2024 (USD MILLION)
TABLE 174. SOUTH AFRICA UPADACITINIB MARKET SIZE, BY END-USERS, 2025-2030 (USD MILLION)
TABLE 175. SOUTH AFRICA UPADACITINIB MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 176. SOUTH AFRICA UPADACITINIB MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 177. DENMARK UPADACITINIB MARKET SIZE, BY FORM, 2018-2024 (USD MILLION)
TABLE 178. DENMARK UPADACITINIB MARKET SIZE, BY FORM, 2025-2030 (USD MILLION)
TABLE 179. DENMARK UPADACITINIB MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
TABLE 180. DENMARK UPADACITINIB MARKET SIZE, BY THERAPEUTIC AREA, 2025-2030 (USD MILLION)
TABLE 181. DENMARK UPADACITINIB MARKET SIZE, BY END-USERS, 2018-2024 (USD MILLION)
TABLE 182. DENMARK UPADACITINIB MARKET SIZE, BY END-USERS, 2025-2030 (USD MILLION)
TABLE 183. DENMARK UPADACITINIB MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 184. DENMARK UPADACITINIB MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 185. NETHERLANDS UPADACITINIB MARKET SIZE, BY FORM, 2018-2024 (USD MILLION)
TABLE 186. NETHERLANDS UPADACITINIB MARKET SIZE, BY FORM, 2025-2030 (USD MILLION)
TABLE 187. NETHERLANDS UPADACITINIB MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
TABLE 188. NETHERLANDS UPADACITINIB MARKET SIZE, BY THERAPEUTIC AREA, 2025-2030 (USD MILLION)
TABLE 189. NETHERLANDS UPADACITINIB MARKET SIZE, BY END-USERS, 2018-2024 (USD MILLION)
TABLE 190. NETHERLANDS UPADACITINIB MARKET SIZE, BY END-USERS, 2025-2030 (USD MILLION)
TABLE 191. NETHERLANDS UPADACITINIB MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 192. NETHERLANDS UPADACITINIB MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 193. QATAR UPADACITINIB MARKET SIZE, BY FORM, 2018-2024 (USD MILLION)
TABLE 194. QATAR UPADACITINIB MARKET SIZE, BY FORM, 2025-2030 (USD MILLION)
TABLE 195. QATAR UPADACITINIB MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
TABLE 196. QATAR UPADACITINIB MARKET SIZE, BY THERAPEUTIC AREA, 2025-2030 (USD MILLION)
TABLE 197. QATAR UPADACITINIB MARKET SIZE, BY END-USERS, 2018-2024 (USD MILLION)
TABLE 198. QATAR UPADACITINIB MARKET SIZE, BY END-USERS, 2025-2030 (USD MILLION)
TABLE 199. QATAR UPADACITINIB MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 200. QATAR UPADACITINIB MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 201. FINLAND UPADACITINIB MARKET SIZE, BY FORM, 2018-2024 (USD MILLION)
TABLE 202. FINLAND UPADACITINIB MARKET SIZE, BY FORM, 2025-2030 (USD MILLION)
TABLE 203. FINLAND UPADACITINIB MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
TABLE 204. FINLAND UPADACITINIB MARKET SIZE, BY THERAPEUTIC AREA, 2025-2030 (USD MILLION)
TABLE 205. FINLAND UPADACITINIB MARKET SIZE, BY END-USERS, 2018-2024 (USD MILLION)
TABLE 206. FINLAND UPADACITINIB MARKET SIZE, BY END-USERS, 2025-2030 (USD MILLION)
TABLE 207. FINLAND UPADACITINIB MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 208. FINLAND UPADACITINIB MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 209. SWEDEN UPADACITINIB MARKET SIZE, BY FORM, 2018-2024 (USD MILLION)
TABLE 210. SWEDEN UPADACITINIB MARKET SIZE, BY FORM, 2025-2030 (USD MILLION)
TABLE 211. SWEDEN UPADACITINIB MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
TABLE 212. SWEDEN UPADACITINIB MARKET SIZE, BY THERAPEUTIC AREA, 2025-2030 (USD MILLION)
TABLE 213. SWEDEN UPADACITINIB MARKET SIZE, BY END-USERS, 2018-2024 (USD MILLION)
TABLE 214. SWEDEN UPADACITINIB MARKET SIZE, BY END-USERS, 2025-2030 (USD MILLION)
TABLE 215. SWEDEN UPADACITINIB MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 216. SWEDEN UPADACITINIB MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 217. NIGERIA UPADACITINIB MARKET SIZE, BY FORM, 2018-2024 (USD MILLION)
TABLE 218. NIGERIA UPADACITINIB MARKET SIZE, BY FORM, 2025-2030 (USD MILLION)
TABLE 219. NIGERIA UPADACITINIB MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
TABLE 220. NIGERIA UPADACITINIB MARKET SIZE, BY THERAPEUTIC AREA, 2025-2030 (USD MILLION)
TABLE 221. NIGERIA UPADACITINIB MARKET SIZE, BY END-USERS, 2018-2024 (USD MILLION)
TABLE 222. NIGERIA UPADACITINIB MARKET SIZE, BY END-USERS, 2025-2030 (USD MILLION)
TABLE 223. NIGERIA UPADACITINIB MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 224. NIGERIA UPADACITINIB MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 225. EGYPT UPADACITINIB MARKET SIZE, BY FORM, 2018-2024 (USD MILLION)
TABLE 226. EGYPT UPADACITINIB MARKET SIZE, BY FORM, 2025-2030 (USD MILLION)
TABLE 227. EGYPT UPADACITINIB MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
TABLE 228. EGYPT UPADACITINIB MARKET SIZE, BY THERAPEUTIC AREA, 2025-2030 (USD MILLION)
TABLE 229. EGYPT UPADACITINIB MARKET SIZE, BY END-USERS, 2018-2024 (USD MILLION)
TABLE 230. EGYPT UPADACITINIB MARKET SIZE, BY END-USERS, 2025-2030 (USD MILLION)
TABLE 231. EGYPT UPADACITINIB MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 232. EGYPT UPADACITINIB MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 233. TURKEY UPADACITINIB MARKET SIZE, BY FORM, 2018-2024 (USD MILLION)
TABLE 234. TURKEY UPADACITINIB MARKET SIZE, BY FORM, 2025-2030 (USD MILLION)
TABLE 235. TURKEY UPADACITINIB MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
TABLE 236. TURKEY UPADACITINIB MARKET SIZE, BY THERAPEUTIC AREA, 2025-2030 (USD MILLION)
TABLE 237. TURKEY UPADACITINIB MARKET SIZE, BY END-USERS, 2018-2024 (USD MILLION)
TABLE 238. TURKEY UPADACITINIB MARKET SIZE, BY END-USERS, 2025-2030 (USD MILLION)
TABLE 239. TURKEY UPADACITINIB MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 240. TURKEY UPADACITINIB MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 241. ISRAEL UPADACITINIB MARKET SIZE, BY FORM, 2018-2024 (USD MILLION)
TABLE 242. ISRAEL UPADACITINIB MARKET SIZE, BY FORM, 2025-2030 (USD MILLION)
TABLE 243. ISRAEL UPADACITINIB MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
TABLE 244. ISRAEL UPADACITINIB MARKET SIZE, BY THERAPEUTIC AREA, 2025-2030 (USD MILLION)
TABLE 245. ISRAEL UPADACITINIB MARKET SIZE, BY END-USERS, 2018-2024 (USD MILLION)
TABLE 246. ISRAEL UPADACITINIB MARKET SIZE, BY END-USERS, 2025-2030 (USD MILLION)
TABLE 247. ISRAEL UPADACITINIB MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 248. ISRAEL UPADACITINIB MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 249. NORWAY UPADACITINIB MARKET SIZE, BY FORM, 2018-2024 (USD MILLION)
TABLE 250. NORWAY UPADACITINIB MARKET SIZE, BY FORM, 2025-2030 (USD MILLION)
TABLE 251. NORWAY UPADACITINIB MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
TABLE 252. NORWAY UPADACITINIB MARKET SIZE, BY THERAPEUTIC AREA, 2025-2030 (USD MILLION)
TABLE 253. NORWAY UPADACITINIB MARKET SIZE, BY END-USERS, 2018-2024 (USD MILLION)
TABLE 254. NORWAY UPADACITINIB MARKET SIZE, BY END-USERS, 2025-2030 (USD MILLION)
TABLE 255. NORWAY UPADACITINIB MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 256. NORWAY UPADACITINIB MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 257. POLAND UPADACITINIB MARKET SIZE, BY FORM, 2018-2024 (USD MILLION)
TABLE 258. POLAND UPADACITINIB MARKET SIZE, BY FORM, 2025-2030 (USD MILLION)
TABLE 259. POLAND UPADACITINIB MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
TABLE 260. POLAND UPADACITINIB MARKET SIZE, BY THERAPEUTIC AREA, 2025-2030 (USD MILLION)
TABLE 261. POLAND UPADACITINIB MARKET SIZE, BY END-USERS, 2018-2024 (USD MILLION)
TABLE 262. POLAND UPADACITINIB MARKET SIZE, BY END-USERS, 2025-2030 (USD MILLION)
TABLE 263. POLAND UPADACITINIB MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 264. POLAND UPADACITINIB MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 265. SWITZERLAND UPADACITINIB MARKET SIZE, BY FORM, 2018-2024 (USD MILLION)
TABLE 266. SWITZERLAND UPADACITINIB MARKET SIZE, BY FORM, 2025-2030 (USD MILLION)
TABLE 267. SWITZERLAND UPADACITINIB MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
TABLE 268. SWITZERLAND UPADACITINIB MARKET SIZE, BY THERAPEUTIC AREA, 2025-2030 (USD MILLION)
TABLE 269. SWITZERLAND UPADACITINIB MARKET SIZE, BY END-USERS, 2018-2024 (USD MILLION)
TABLE 270. SWITZERLAND UPADACITINIB MARKET SIZE, BY END-USERS, 2025-2030 (USD MILLION)
TABLE 271. SWITZERLAND UPADACITINIB MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 272. SWITZERLAND UPADACITINIB MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 273. ASIA-PACIFIC UPADACITINIB MARKET SIZE, BY FORM, 2018-2024 (USD MILLION)
TABLE 274. ASIA-PACIFIC UPADACITINIB MARKET SIZE, BY FORM, 2025-2030 (USD MILLION)
TABLE 275. ASIA-PACIFIC UPADACITINIB MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
TABLE 276. ASIA-PACIFIC UPADACITINIB MARKET SIZE, BY THERAPEUTIC AREA, 2025-2030 (USD MILLION)
TABLE 277. ASIA-PACIFIC UPADACITINIB MARKET SIZE, BY END-USERS, 2018-2024 (USD MILLION)
TABLE 278. ASIA-PACIFIC UPADACITINIB MARKET SIZE, BY END-USERS, 2025-2030 (USD MILLION)
TABLE 279. ASIA-PACIFIC UPADACITINIB MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 280. ASIA-PACIFIC UPADACITINIB MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 281. ASIA-PACIFIC UPADACITINIB MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 282. ASIA-PACIFIC UPADACITINIB MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 283. CHINA UPADACITINIB MARKET SIZE, BY FORM, 2018-2024 (USD MILLION)
TABLE 284. CHINA UPADACITINIB MARKET SIZE, BY FORM, 2025-2030 (USD MILLION)
TABLE 285. CHINA UPADACITINIB MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
TABLE 286. CHINA UPADACITINIB MARKET SIZE, BY THERAPEUTIC AREA, 2025-2030 (USD MILLION)
TABLE 287. CHINA UPADACITINIB MARKET SIZE, BY END-USERS, 2018-2024 (USD MILLION)
TABLE 288. CHINA UPADACITINIB MARKET SIZE, BY END-USERS, 2025-2030 (USD MILLION)
TABLE 289. CHINA UPADACITINIB MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 290. CHINA UPADACITINIB MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 291. INDIA UPADACITINIB MARKET SIZE, BY FORM, 2018-2024 (USD MILLION)
TABLE 292. INDIA UPADACITINIB MARKET SIZE, BY FORM, 2025-2030 (USD MILLION)
TABLE 293. INDIA UPADACITINIB MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
TABLE 294. INDIA UPADACITINIB MARKET SIZE, BY THERAPEUTIC AREA, 2025-2030 (USD MILLION)
TABLE 295. INDIA UPADACITINIB MARKET SIZE, BY END-USERS, 2018-2024 (USD MILLION)
TABLE 296. INDIA UPADACITINIB MARKET SIZE, BY END-USERS, 2025-2030 (USD MILLION)
TABLE 297. INDIA UPADACITINIB MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 298. INDIA UPADACITINIB MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 299. JAPAN UPADACITINIB MARKET SIZE, BY FORM, 2018-2024 (USD MILLION)
TABLE 300. JAPAN UPADACITINIB MARKET SIZE, BY FORM, 2025-2030 (USD MILLION)
TABLE 301. JAPAN UPADACITINIB MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
TABLE 302. JAPAN UPADACITINIB MARKET SIZE, BY THERAPEUTIC AREA, 2025-2030 (USD MILLION)
TABLE 303. JAPAN UPADACITINIB MARKET SIZE, BY END-USERS, 2018-2024 (USD MILLION)
TABLE 304. JAPAN UPADACITINIB MARKET SIZE, BY END-USERS, 2025-2030 (USD MILLION)
TABLE 305. JAPAN UPADACITINIB MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 306. JAPAN UPADACITINIB MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 307. AUSTRALIA UPADACITINIB MARKET SIZE, BY FORM, 2018-2024 (USD MILLION)
TABLE 308. AUSTRALIA UPADACITINIB MARKET SIZE, BY FORM, 2025-2030 (USD MILLION)
TABLE 309. AUSTRALIA UPADACITINIB MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
TABLE 310. AUSTRALIA UPADACITINIB MARKET SIZE, BY THERAPEUTIC AREA, 2025-2030 (USD MILLION)
TABLE 311. AUSTRALIA UPADACITINIB MARKET SIZE, BY END-USERS, 2018-2024 (USD MILLION)
TABLE 312. AUSTRALIA UPADACITINIB MARKET SIZE, BY END-USERS, 2025-2030 (USD MILLION)
TABLE 313. AUSTRALIA UPADACITINIB MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 314. AUSTRALIA UPADACITINIB MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 315. SOUTH KOREA UPADACITINIB MARKET SIZE, BY FORM, 2018-2024 (USD MILLION)
TABLE 316. SOUTH KOREA UPADACITINIB MARKET SIZE, BY FORM, 2025-2030 (USD MILLION)
TABLE 317. SOUTH KOREA UPADACITINIB MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
TABLE 318. SOUTH KOREA UPADACITINIB MARKET SIZE, BY THERAPEUTIC AREA, 2025-2030 (USD MILLION)
TABLE 319. SOUTH KOREA UPADACITINIB MARKET SIZE, BY END-USERS, 2018-2024 (USD MILLION)
TABLE 320. SOUTH KOREA UPADACITINIB MARKET SIZE, BY END-USERS, 2025-2030 (USD MILLION)
TABLE 321. SOUTH KOREA UPADACITINIB MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 322. SOUTH KOREA UPADACITINIB MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 323. INDONESIA UPADACITINIB MARKET SIZE, BY FORM, 2018-2024 (USD MILLION)
TABLE 324. INDONESIA UPADACITINIB MARKET SIZE, BY FORM, 2025-2030 (USD MILLION)
TABLE 325. INDONESIA UPADACITINIB MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
TABLE 326. INDONESIA UPADACITINIB MARKET SIZE, BY THERAPEUTIC AREA, 2025-2030 (USD MILLION)
TABLE 327. INDONESIA UPADACITINIB MARKET SIZE, BY END-USERS, 2018-2024 (USD MILLION)
TABLE 328. INDONESIA UPADACITINIB MARKET SIZE, BY END-USERS, 2025-2030 (USD MILLION)
TABLE 329. INDONESIA UPADACITINIB MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 330. INDONESIA UPADACITINIB MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 331. THAILAND UPADACITINIB MARKET SIZE, BY FORM, 2018-2024 (USD MILLION)
TABLE 332. THAILAND UPADACITINIB MARKET SIZE, BY FORM, 2025-2030 (USD MILLION)
TABLE 333. THAILAND UPADACITINIB MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
TABLE 334. THAILAND UPADACITINIB MARKET SIZE, BY THERAPEUTIC AREA, 2025-2030 (USD MILLION)
TABLE 335. THAILAND UPADACITINIB MARKET SIZE, BY END-USERS, 2018-2024 (USD MILLION)
TABLE 336. THAILAND UPADACITINIB MARKET SIZE, BY END-USERS, 2025-2030 (USD MILLION)
TABLE 337. THAILAND UPADACITINIB MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 338. THAILAND UPADACITINIB MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 339. PHILIPPINES UPADACITINIB MARKET SIZE, BY FORM, 2018-2024 (USD MILLION)
TABLE 340. PHILIPPINES UPADACITINIB MARKET SIZE, BY FORM, 2025-2030 (USD MILLION)
TABLE 341. PHILIPPINES UPADACITINIB MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
TABLE 342. PHILIPPINES UPADACITINIB MARKET SIZE, BY THERAPEUTIC AREA, 2025-2030 (USD MILLION)
TABLE 343. PHILIPPINES UPADACITINIB MARKET SIZE, BY END-USERS, 2018-2024 (USD MILLION)
TABLE 344. PHILIPPINES UPADACITINIB MARKET SIZE, BY END-USERS, 2025-2030 (USD MILLION)
TABLE 345. PHILIPPINES UPADACITINIB MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 346. PHILIPPINES UPADACITINIB MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 347. MALAYSIA UPADACITINIB MARKET SIZE, BY FORM, 2018-2024 (USD MILLION)
TABLE 348. MALAYSIA UPADACITINIB MARKET SIZE, BY FORM, 2025-2030 (USD MILLION)
TABLE 349. MALAYSIA UPADACITINIB MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
TABLE 350. MALAYSIA UPADACITINIB MARKET SIZE, BY THERAPEUTIC AREA, 2025-2030 (USD MILLION)
TABLE 351. MALAYSIA UPADACITINIB MARKET SIZE, BY END-USERS, 2018-2024 (USD MILLION)
TABLE 352. MALAYSIA UPADACITINIB MARKET SIZE, BY END-USERS, 2025-2030 (USD MILLION)
TABLE 353. MALAYSIA UPADACITINIB MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 354. MALAYSIA UPADACITINIB MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 355. SINGAPORE UPADACITINIB MARKET SIZE, BY FORM, 2018-2024 (USD MILLION)
TABLE 356. SINGAPORE UPADACITINIB MARKET SIZE, BY FORM, 2025-2030 (USD MILLION)
TABLE 357. SINGAPORE UPADACITINIB MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
TABLE 358. SINGAPORE UPADACITINIB MARKET SIZE, BY THERAPEUTIC AREA, 2025-2030 (USD MILLION)
TABLE 359. SINGAPORE UPADACITINIB MARKET SIZE, BY END-USERS, 2018-2024 (USD MILLION)
TABLE 360. SINGAPORE UPADACITINIB MARKET SIZE, BY END-USERS, 2025-2030 (USD MILLION)
TABLE 361. SINGAPORE UPADACITINIB MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 362. SINGAPORE UPADACITINIB MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 363. VIETNAM UPADACITINIB MARKET SIZE, BY FORM, 2018-2024 (USD MILLION)
TABLE 364. VIETNAM UPADACITINIB MARKET SIZE, BY FORM, 2025-2030 (USD MILLION)
TABLE 365. VIETNAM UPADACITINIB MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
TABLE 366. VIETNAM UPADACITINIB MARKET SIZE, BY THERAPEUTIC AREA, 2025-2030 (USD MILLION)
TABLE 367. VIETNAM UPADACITINIB MARKET SIZE, BY END-USERS, 2018-2024 (USD MILLION)
TABLE 368. VIETNAM UPADACITINIB MARKET SIZE, BY END-USERS, 2025-2030 (USD MILLION)
TABLE 369. VIETNAM UPADACITINIB MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 370. VIETNAM UPADACITINIB MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 371. TAIWAN UPADACITINIB MARKET SIZE, BY FORM, 2018-2024 (USD MILLION)
TABLE 372. TAIWAN UPADACITINIB MARKET SIZE, BY FORM, 2025-2030 (USD MILLION)
TABLE 373. TAIWAN UPADACITINIB MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (U

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Upadacitinib Market report include:
  • AbbVie Inc.
  • Cayman Chemical Company
  • Bayer AG
  • Boehringer Ingelheim GmbH
  • Bristol-Myers Squibb Company
  • Cipla Limited
  • Daiichi Sankyo Company, Limited
  • GlaxoSmithKline plc
  • Incyte Corporation
  • Merck & Co., Inc.
  • Pfizer Inc
  • Regeneron Pharmaceuticals, Inc.
  • Sun Pharmaceutical Industries Ltd.
  • Takeda Pharmaceutical Company Limited
  • Aarti Pharmalabs Limited
  • Anant Pharmaceuticals Pvt. Ltd.
  • BOCSCI Inc.

Table Information

Report AttributeDetails
No. of Pages183
PublishedAugust 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 325.2 million
Forecasted Market Value ( USD ) by 2030 $ 466.22 million
Compound Annual Growth Rate7.4%
Regions CoveredGlobal
No. of Companies Mentioned18

Related Topics

Related Reports

Upadacitinib Global Market Report 2025 - Product Image

Upadacitinib Global Market Report 2025

  • Report
  • 175 Pages
  • Global
From
Vitiligo Pipeline Analysis Report - Product Image

Vitiligo Pipeline Analysis Report

  • Report
  • 150 Pages
  • Global
From
Vitiligo Drug Pipeline Analysis Report 2025 - Product Image

Vitiligo Drug Pipeline Analysis Report 2025

  • Drug Pipelines
  • 200 Pages
  • Global
From
Crohn's Disease Therapeutics Market by Therapy Class (Biologics, Immunosuppressants, Small Molecules), Route Of Administration (Intravenous, Oral, Subcutaneous), Distribution Channel, End User - Global Forecast 2025-2030 - Product Image

Crohn's Disease Therapeutics Market by Therapy Class (Biologics, Immunosuppressants, Small Molecules), Route Of Administration (Intravenous, Oral, Subcutaneous), Distribution Channel, End User - Global Forecast 2025-2030

  • Report
  • 196 Pages
  • Global
From
Alopecia Areata: Opportunity Assessment and Forecast to 2033 - Product Image

Alopecia Areata: Opportunity Assessment and Forecast to 2033

  • Report
  • 81 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.